Said Darwazah Acquires 10,000 Shares of Hikma Pharmaceuticals Plc (HIK) Stock
Hikma Pharmaceuticals Plc (LON:HIK) insider Said Darwazah acquired 10,000 shares of the firm’s stock in a transaction dated Wednesday, September 28th. The shares were acquired at an average price of GBX 2,085 ($27.22) per share, for a total transaction of £208,500 ($272,157.68).
Said Darwazah also recently made the following trade(s):
- On Monday, September 26th, Said Darwazah acquired 50,000 shares of Hikma Pharmaceuticals Plc stock. The shares were acquired at an average price of GBX 2,078 ($27.12) per share, for a total transaction of £1,039,000 ($1,356,219.81).
Hikma Pharmaceuticals Plc (LON:HIK) opened at 2049.00 on Friday. Hikma Pharmaceuticals Plc has a 52-week low of GBX 1,575.00 and a 52-week high of GBX 2,703.00. The stock’s market capitalization is GBX 4.63 billion. The firm has a 50-day moving average price of GBX 2,176.69 and a 200 day moving average price of GBX 2,245.79.
Several research firms have recently issued reports on HIK. Numis Securities Ltd cut Hikma Pharmaceuticals Plc to a “hold” rating and set a GBX 2,660 ($34.72) price objective on the stock. in a report on Thursday, August 4th. Jefferies Group reaffirmed a “buy” rating and issued a GBX 2,990 ($39.03) target price on shares of Hikma Pharmaceuticals Plc in a research report on Thursday, August 4th. JPMorgan Chase & Co. cut their target price on Hikma Pharmaceuticals Plc from GBX 2,800 ($36.55) to GBX 2,550 ($33.29) and set an “overweight” rating on the stock in a research report on Thursday, August 4th. Barclays PLC reaffirmed an “overweight” rating and issued a GBX 2,800 ($36.55) target price on shares of Hikma Pharmaceuticals Plc in a research report on Thursday, August 4th. Finally, Citigroup Inc. lowered Hikma Pharmaceuticals Plc to a “neutral” rating and set a GBX 2,600 ($33.94) target price on the stock. in a research report on Thursday, August 4th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of GBX 2,520.90 ($32.91).
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.
Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.